Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Predicting CAR T-cell therapy outcomes in large B-cell lymphoma using pre-infusion clinical and inflammatory markers: A machine learning approach with explainable artificial intelligence

Blood (2025) 146 (Supplement 1): 2569.

https://doi.org/10.1182/blood-2025-2569

Published: 2025

Journal Articles

Cell differentiation stage drives mechanisms of apoptosis evasion in Waldenström macroglobulinemia

Cristina Frusteri, Aleix Real, Ferran Nadeu, Laura Fumagalli, Valentina Manconi, Ali Jafari Kia, Eleonora Terrabuio, Alessio Montresor, Maria Pia Manto, Eleonora Gugole, Angela Mercuri, Laura Bonaldi, Gabriela Constantin, Mauro Krampera, Carlo Visco, Maria Teresa Scupoli, Carlo Laudanna, Isacco Ferrarini

Blood (2025) 146 (Supplement 1): 1774.

https://doi.org/10.1182/blood-2025-1774

Published: 2025

Journal Articles

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study

Blood (2025) 146 (Supplement 1): 7636.

https://doi.org/10.1182/blood-2025-7636

Published: 2025

Journal Articles

Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study

Blood (2025) 146 (Supplement 1): 3722.

https://doi.org/10.1182/blood-2025-3722

Published: 2025

Journal Articles

Anti-CD19 CAR T cells therapy can overcome the prognostic impact of CD5-positivity in patients with diffuse large B cell lymphomas: Results from the multicenter prospective CAR-T SIE study

Blood (2025) 146 (Supplement 1): 3721.

https://doi.org/10.1182/blood-2025-3721

Published: 2025

Journal Articles

It's not yet time to abandon ruxolitinib in anemic myelofibrosis: Predictive factors of erythroid response to standard anemia-directed therapies combined with ruxolitinib

Massimiliano Bonifacio, Alda Strazimiri, Giuseppe Carli, Luigi Scaffidi, Gessica Marchesini, Ilaria Nichele, Gian Luca Morelli, Melissa Bergnach, Luca Tosoni, Renato Fanin, Alberto Tosetto, Mauro Krampera, Mario Tiribelli

Blood (2025) 146 (Supplement 1): 3820.

https://doi.org/10.1182/blood-2025-3820

Published: 2025

Journal Articles

Absence of lymphocytosis after starting treatment with cbtki is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12.

Blood (2025) 146 (Supplement 1): 5671.

https://doi.org/10.1182/blood-2025-5671

Published: 2025

Journal Articles

High Ferritin and C-Reactive Protein Levels Result in Poor Clinical Outcome in R/R Large B-Cell Lymphoma Patients Despite Significant Anti-CD19 CAR-T Cell In Vivo Expansion

Blood (2024) 144 (Supplement 1): 4786.

https://doi.org/10.1182/blood-2024-201399

Published: 2024

Journal Articles

Real-Life MRD Impact in Favorable and Intermediate ELN 2022 Risk AML: Analysis of an Intensive Treated Cohort from Acute Leukemia Registry of the “Rete Ematologica Veneta” Network (REV-AL01)

Sara Consolo, Matteo Leoncin, Laura Forlani, Giulia Ciotti, Daniela Banegas Guallpa, Ilaria Tanasi, Carmela Gurrieri, Michele Gottardi, Mauro Krampera, Livio Trentin, Cristina Skert

Blood (2024) 144 (Supplement 1): 6177.

https://doi.org/10.1182/blood-2024-208277

Published: 2024

Journal Articles

Outcomes of CAR T-Cells Therapy in High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas: A Weighted Comparison Analysis from CAR-T SIE Study

Blood (2024) 144 (Supplement 1): 3131.

https://doi.org/10.1182/blood-2024-199720

Published: 2024

Journal Articles

Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study

Blood (2024) 144 (Supplement 1): 4797.

https://doi.org/10.1182/blood-2024-207660

Published: 2024

Journal Articles

Efficacy of Venetoclax-Based Therapy Followed By Allogeneic Transplantation in Newly Diagnosed and Relapsed/Refractory AML Patients

Blood (2024) 144 (Supplement 1): 6038.

https://doi.org/10.1182/blood-2024-205250

Published: 2024

Journal Articles

Impact of Concurrent and Previous Multidrug Resistant Bacteria Colonization in Adult Allogenic Hematopoietic Stem Cell Transplant Patients with Acute Leukemia: A Single Center Retrospective Study

Alessandra Vatteroni, Alberto Schena, Fulvia Mazzaferri, Francesca Lutteri, Simone Cesaro, Mauro Krampera, Fabio Benedetti, Cristina Tecchio

Blood (2023) 142 (Supplement 1): 6966.

https://doi.org/10.1182/blood-2023-187359

Published: 2023

Journal Articles

Progression-Free Survival but Not Overall Survival Is Superior in Relapsed/Refractory Large B-Cell Lymphomas Treated with Axicabtagene Ciloleucel Compared to Tisagenlecleucel: Results of the CART-SIE Real Life Italian Study

Blood (2023) 142 (Supplement 1): 2118.

https://doi.org/10.1182/blood-2023-189300

Published: 2023

Journal Articles

Multiparametric Flow Cytometry-MRD Assay: Lesson from Phase II Trail REL AML 001

Blood (2023) 142 (Supplement 1): 5997.

https://doi.org/10.1182/blood-2023-185555

Published: 2023

Journal Articles

Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: The "RAMP” Multicenter Prospective Study

Blood (2022) 140 (Supplement 1): 9726–9728.

https://doi.org/10.1182/blood-2022-165303

Published: 2022

Journal Articles

Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results

Blood (2022) 140 (Supplement 1): 9054–9056.

https://doi.org/10.1182/blood-2022-160024

Published: 2022

Journal Articles

Treatment of Patients with Relapsed or Refractory Primary CNS Lymphoma (rrPCNSL) Enrolled in the Randomized Trials of the International Extranodal Lymphoma Study Group (IELSG)

Blood (2021) 138 (Supplement 1): 1417.

https://doi.org/10.1182/blood-2021-147822

Published: 2021

Journal Articles

Peripheral Blasts Are Associated with Response to Ruxolitinib and Outcome in Patients with Chronic-Phase Myelofibrosis

Blood (2021) 138 (Supplement 1): 3624.

https://doi.org/10.1182/blood-2021-152420

Published: 2021

Journal Articles

BCR-ABL1 Levels at First Month after TKI Discontinuation Predict Subsequent Maintenance of Treatment-Free Remission: A Study from the "Gruppo Triveneto LMC"

Sara Di Giusto, PhD, Eleonora Toffoletti, MD, Massimiliano Bonifacio, MD, Gianni Binotto, MD, Maria Cristina Miggiano, MD, Elisabetta Calistri, MD, Manuela Stulle, MD, Anna Ermacora, MD, Rossella Stella, MD, Luigi Scaffidi, MD, Fabio D'Amore, MD, Giorgia Scotton, MD, Giovanna De Matteis, PhD, Roberta Bertorelle, PhD, Renato Fanin, MD, Mauro Krampera, MD PhD, Gianpietro Semenzato, MD, Daniela Damiani, MD, Mario Tiribelli, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-135968

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Predicting CAR T-cell therapy outcomes in large B-cell lymphoma using pre-infusion clinical and inflammatory markers: A machine learning approach with explainable artificial intelligence

Cell differentiation stage drives mechanisms of apoptosis evasion in Waldenström macroglobulinemia

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study

Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study

Anti-CD19 CAR T cells therapy can overcome the prognostic impact of CD5-positivity in patients with diffuse large B cell lymphomas: Results from the multicenter prospective CAR-T SIE study

It's not yet time to abandon ruxolitinib in anemic myelofibrosis: Predictive factors of erythroid response to standard anemia-directed therapies combined with ruxolitinib

Absence of lymphocytosis after starting treatment with cbtki is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12.

High Ferritin and C-Reactive Protein Levels Result in Poor Clinical Outcome in R/R Large B-Cell Lymphoma Patients Despite Significant Anti-CD19 CAR-T Cell In Vivo Expansion

Real-Life MRD Impact in Favorable and Intermediate ELN 2022 Risk AML: Analysis of an Intensive Treated Cohort from Acute Leukemia Registry of the “Rete Ematologica Veneta” Network (REV-AL01)

Outcomes of CAR T-Cells Therapy in High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas: A Weighted Comparison Analysis from CAR-T SIE Study

Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study

Efficacy of Venetoclax-Based Therapy Followed By Allogeneic Transplantation in Newly Diagnosed and Relapsed/Refractory AML Patients

Impact of Concurrent and Previous Multidrug Resistant Bacteria Colonization in Adult Allogenic Hematopoietic Stem Cell Transplant Patients with Acute Leukemia: A Single Center Retrospective Study

Progression-Free Survival but Not Overall Survival Is Superior in Relapsed/Refractory Large B-Cell Lymphomas Treated with Axicabtagene Ciloleucel Compared to Tisagenlecleucel: Results of the CART-SIE Real Life Italian Study

Multiparametric Flow Cytometry-MRD Assay: Lesson from Phase II Trail REL AML 001

Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: The "RAMP” Multicenter Prospective Study

Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results

Treatment of Patients with Relapsed or Refractory Primary CNS Lymphoma (rrPCNSL) Enrolled in the Randomized Trials of the International Extranodal Lymphoma Study Group (IELSG)

Peripheral Blasts Are Associated with Response to Ruxolitinib and Outcome in Patients with Chronic-Phase Myelofibrosis

BCR-ABL1 Levels at First Month after TKI Discontinuation Predict Subsequent Maintenance of Treatment-Free Remission: A Study from the "Gruppo Triveneto LMC"

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only